Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Phase 4, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Recombinant Alpha-Galactosidase A (Agalsidase Beta, FABRAZYME) in Heterozygous Females for Fabry Disease

NCT00487630 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.

NCT NCT00487630
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00487630 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Phase 4, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Recombinant Alpha-Galactosidase A (Agalsidase Beta, FABRAZYME) in Heterozygous Females for Fabry Disease
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Phase 4
Overall status
Unknown status
Start date
June 30, 2005
Completion date
June 30, 2009
Enrollment
34 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

fabry disease